The development of drugs such as FcRn antagonists is based on this process, which promotes the reduction in circulating IgG by competitively blocking the binding of Ab to FcRn with high affinity for FcRn, thereby achieving the effect of alleviating MG symptoms (Fichtner et al., 2020). Here, FCGRT is linked to myasthenia gravis.